Supplements and Featured Publications

2021 ASH Annual Meeting: CAR T-Cell Therapy
Volume: 1
Issue: 1
The 2021 ASH Annual Meeting: CAR T-Cell Therapy priority report is a digital version of the print publication spanning some of the groundbreaking abstracts in CAR T-cell therapy that were presented during the conference.

My Treatment Approach: Optimal Second- and Third-Line Treatment Options of cGVHD
Volume: 1
Issue: 1
The My Treatment Approach: Optimal Second- and Third-Line Treatment Options of cGVHD publication covers some of the latest and practice-changing advances in the treatment for patients with chronic graft-vs-host disease following recent regulatory decisions and data read outs from pivotal clinical trials, as well as expert insights on how they approach therapy on an individualized basis.

2021 EBMT Annual Meeting
Volume: 1
Issue: 1
Coverage of the 2021 EBMT Annual Meeting, held virtually March 14-17, 2021.

Updates in Relapsed/Refractory AML
Volume: 1
Issue: 1
Advertisement
Advertisement
Trending on OncLive
1
Long-Term Cilta-Cel Data Show Low Rates of PFS Events in Standard-Risk R/R Myeloma
2
FDA Updates Axi-Cel Label to Remove Limitation of Use in R/R PCNSL
3
Nonresponse to Bridging Therapy and Peak ALC After Cilta-Cel Are Associated With Neurotoxicity, NRM in Myeloma
4
Real-World Data Support Clinical Benefit With Lifileucel in Previously Treated Advanced Melanoma
5

